Professor Tony Gershlick

Honorary Professor of Interventional Cardiology, University of Leicester and Consultant Cardiologist, University Hospitals of Leicester NHS Trust

BSc, Pharmacological Biochemistry 1973
MB BS 1976
MRCP 1980
FRCP 1994 

Tel: 0116 250 2677

Email: agershlick@aol.com

Address: Department of Cardiovascular Sciences, University of Leicester,  
Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP

For University related enquiries please email, Louise Goddard, or telephone 0116 258 3045.
Fo NHS enquiries please email Michelle Moore (michelle.moore@uhl-tr.nhs.uk), Tel: 0116 258 3887. 

Research Interests

  • Ischemic Heart Disease
  • Coronary intervention
  • Novel intracoronary stents
  • Clinical trials
  • Novel Antiplatelet agents
  • Stent thrombosis and restenosis

External Positions

  • British Cardiovascular Intervention Society (BCIS)
    Council Member 1994-2000
    Seconded member 2000-2004 
    Scientific Advisor 2004-2009
    Scientific Information Officer (BCIS) 2005-
    BCIS R&D Committee 2007-
    BCIS Audit Group 2009-2012
  • British Cardiovascular Society (formerly British Cardiac Society)
    British Cardiac Society Academic Committee 2003-
    Council Member 2004-08
    Programme Committee 2006–2012
  • Department of Health
    Member Steering and the Data Oversight Committee National Infarct  Angioplasty Project  (NIAP)  2003-07  
    NIAP Steering and Data Overview Committee 2006 -2008       
    NIAP Academic Group 2008- 
  • National Institute for Clinical Excellence (N.I.C.E)
    Medical Expert ‘Stents’ and ‘Drug Eluting Stents’ 2002-2004, 2006, 2008
    NICE Working party and Scoping Committee 2008
    Medical expert new antiplatelet agents Prasugrel (2009) Tricagrelor (2011)
  • British Heart Foundation
    Project Grants Committee  2006-2010
  • Medical Research Council
    Panel Member DPFS Awards 2010-2014
  • European Heart Journal
    Editorial Board 2008-
  • European Society of Cardiology 
    European representative on the Faculty Guidelines Committee 2005
    AHA/ACC  Guidelines Committee
    European PCI Scientific Committee (proposed 2006-)
    Collaborative founder – European CTO club 2007- 
    Council member EAPCI Scientific group (ESC affiliated) 2009-2010
  • Other National and International Activities 
    Initiator first Live National Course on left Main Stem Angioplasty 2003
    Initiator first Live National Course on Chronic Total Occlusions 2003 
    Presenter of live interventional cases to TCT Washington, 2000, 2003, 2005
    Live case transmission to ACI 2013

Key Publications

Gershlick AH, Banning AP, Myat A, Verheugt FW, Gersh BJ. Reperfusion therapy for STEMI: is there still a role for thrombolysis in the era of primary percutaneous coronary intervention? Lancet. 2013 Aug 17;382(9892):624-32.

Armstrong PW, Gershlick AH, Goldstein P, Wilcox R, Danays T, Lambert Y, Sulimov V, Rosell Ortiz F, Ostojic M, Welsh RC, Carvalho AC, Nanas J, Arntz HR, Halvorsen S, Huber K, Grajek S, Fresco C, Bluhmki E, Regelin A, Vandenberghe K, Bogaerts K, Van de Werf F; STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013 Apr 11;368(15):1379-87

Kelly DJ, McCann GP, Blackman D, Curzen NP, Dalby M, Greenwood JP, Fairbrother K, Shipley L, Kelion A, Heatherington S, Khan JN, Nazir S, Alahmar A, Flather M, Swanton H, Schofield P, Gunning M, Hall R, Gershlick AH. Complete Versus culprit-Lesion only PRimary PCI Trial (CVLPRIT): a multicentre trial testing management strategies when multivessel disease is detected at the time of primary PCI: rationale and design. EuroIntervention. 2013 Feb 22;8(10):1190-8.

Steg PG, James SK, Atar D, Badano LP, Blömstrom-Lundqvist C, Borger MA, Di Mario C, Dickstein K, Ducrocq G, Fernandez-Aviles F, Gershlick AH, Giannuzzi P, Halvorsen S, Huber K, Juni P, Kastrati A, Knuuti J, Lenzen MJ, Mahaffey KW, Valgimigli M, van 't Hof A, Widimsky P, Zahger D. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC) Eur Heart J. 2012 Oct;33(20):2569-619.

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary interventionJACC Cardiovasc Interv. 2011 Feb 4 2 191-7

Carver A, Rafelt S, Gershlick AH, Fairbrother KL, Hughes S, Wilcox R; REACT Investigators. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol. 2009 Jul 7;54(2):118-26.

Links

Recent papers

Return to Cardiovascular Theme pages

 

Share this page: